| pubmed-article:12759558 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12759558 | lifeskim:mentions | umls-concept:C0011570 | lld:lifeskim |
| pubmed-article:12759558 | lifeskim:mentions | umls-concept:C0587184 | lld:lifeskim |
| pubmed-article:12759558 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:12759558 | pubmed:dateCreated | 2003-5-21 | lld:pubmed |
| pubmed-article:12759558 | pubmed:abstractText | Patients with major depressive disorder (MDD) may have significant differences in cholesterol levels compared with healthy controls. A previous study by our group reported that depressed patients with elevated cholesterol levels (>or=200 mg/dl) were significantly more likely to be nonresponders to fluoxetine treatment than depressed patients with nonelevated cholesterol levels. However, very little is known regarding cholesterol in patients with treatment-resistant depression (TRD). The purpose of this study was to compare cholesterol levels at baseline between depressed patients with and without TRD and to test whether cholesterol levels at baseline can predict clinical response in patients with TRD treated with open-label nortriptyline (NT). | lld:pubmed |
| pubmed-article:12759558 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12759558 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12759558 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12759558 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12759558 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12759558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12759558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12759558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12759558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12759558 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12759558 | pubmed:issn | 0302-282X | lld:pubmed |
| pubmed-article:12759558 | pubmed:author | pubmed-author:NierenbergAnd... | lld:pubmed |
| pubmed-article:12759558 | pubmed:author | pubmed-author:PetersenTimot... | lld:pubmed |
| pubmed-article:12759558 | pubmed:author | pubmed-author:PapakostasGeo... | lld:pubmed |
| pubmed-article:12759558 | pubmed:author | pubmed-author:AlpertJonatha... | lld:pubmed |
| pubmed-article:12759558 | pubmed:author | pubmed-author:FavaMaurizioM | lld:pubmed |
| pubmed-article:12759558 | pubmed:author | pubmed-author:SonawallaSham... | lld:pubmed |
| pubmed-article:12759558 | pubmed:author | pubmed-author:MerensWendeli... | lld:pubmed |
| pubmed-article:12759558 | pubmed:author | pubmed-author:IosifescuDan... | lld:pubmed |
| pubmed-article:12759558 | pubmed:copyrightInfo | Copyright 2003 S. Karger AG, Basel | lld:pubmed |
| pubmed-article:12759558 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12759558 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:12759558 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12759558 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12759558 | pubmed:pagination | 146-51 | lld:pubmed |
| pubmed-article:12759558 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:meshHeading | pubmed-meshheading:12759558... | lld:pubmed |
| pubmed-article:12759558 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12759558 | pubmed:articleTitle | Serum cholesterol in treatment-resistant depression. | lld:pubmed |
| pubmed-article:12759558 | pubmed:affiliation | Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. gpapakostas@partners.org | lld:pubmed |
| pubmed-article:12759558 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12759558 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12759558 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:12759558 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12759558 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12759558 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12759558 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12759558 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12759558 | lld:pubmed |
